News
VRDN
30.87
+1.28%
0.39
Is Viridian Therapeutics (VRDN) Undervalued Following Its Promising VRDN 008 Phase 1 Results?
Simply Wall St · 3d ago
How Phase 1 Success At Viridian Therapeutics (VRDN) Has Changed Its Investment Story
Simply Wall St · 4d ago
Viridian Therapeutics Price Target Raised to $44.00/Share From $42.00 by Wedbush
Dow Jones · 4d ago
Viridian Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones · 4d ago
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $44
Benzinga · 4d ago
Viridian Therapeutics Is Maintained at Overweight by Wells Fargo
Dow Jones · 4d ago
Viridian Therapeutics Price Target Raised to $39.00/Share From $34.00 by Wells Fargo
Dow Jones · 4d ago
Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $39
Benzinga · 4d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Editas Medicine (EDIT) and Praxis Precision Medicines (PRAX)
TipRanks · 4d ago
Viridian Therapeutics, Inc. Announces Positive Phase 1 Results for VRDN-008
NASDAQ · 5d ago
Viridian Therapeutics Stock Rallies on Positive VRDN-008 Trial Results, Eyes 8-Week Dosing
Benzinga · 5d ago
Analysts Are Bullish on Top Healthcare Stocks: Viridian Therapeutics (VRDN), Cormedix (CRMD)
TipRanks · 5d ago
Viridian Therapeutics Consensus Price Target Increased by 15.16% to $42.52
NASDAQ · 5d ago
Viridian Reports Positive Phase 1 Results for VRDN-008
TipRanks · 5d ago
Viridian Therapeutics announces phase 1 results for VRDN-008
TipRanks · 5d ago
Viridian Therapeutics Announced Phase 1 Results For VRDN-008; Demonstrated Deep And Sustained IGG Reduction Through 8 Weeks After Subcutaneous Dosing, With 74% Reduction At Peak
Benzinga · 5d ago
Weekly Report: what happened at VRDN last week (1102-1106)?
Weekly Report · 5d ago
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
Barchart · 6d ago
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
Simply Wall St · 6d ago
Viridian Therapeutics To Present VRDN-008 Phase 1 Data And Outline FcRn Portfolio Development Plans On Monday, November 9, 2026, At 8:00 a.m. ET
Benzinga · 11/06 21:02
More
Webull provides a variety of real-time VRDN stock news. You can receive the latest news about Viridian Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.